**8. Conclusions**

Over the last decade, proteomic studies have become an important means for understanding the biology and pathophysiology of many proteins. The characterization and identification of key players prompted the understanding of the molecular basis of pathologies and helped the development of improved therapeutic approaches for patients. We described here the molecular partners that interact either directly or indirectly with the five canalicular ABC transporters (ABCB11, ABCB4, ABCG5/G8, ABCB1 and ABCC2) and regulate their folding, trafficking, stability and function (Table 1). Nowadays, an important amount of information regarding the genetics of ABC transporters is gathered. We expect that proteomic approaches merged with genomic studies will be a powerful tool in the development of personalized treatment for patients with biliary diseases related to canalicular ABC transporter defects.


**Table 1.** Molecular partners of canalicular ABC transporters.


### **Table 1.** *Cont.*

<sup>1</sup> See the main text for full names of the proteins.

**Author Contributions:** A.B.S., A.B. and E.M. designed and wrote the manuscript. T.A.-S. and T.F. supervised this work. M.L., J.-L.D., E.G. and E.J. provided significant intellectual contributions. All authors have read and agreed to the published version of the manuscript.

**Funding:** A.B.S. and E.M. were supported by the Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation. A.B was supported by the German Research Foundation, Grant Number DFG Project-ID 403224013, SFB 1382, and CRC296. T.F. was supported by grants from the Agence Nationale de la Recherche (ANR-15-CE14-0008-01) and the French Association for the Study of the Liver (AFEF). T.A.-S. was supported by grants from Fondation pour la Recherche Médicale (FRM-EQU-2020-03010517) and the Association Mucoviscidose-ABCF2.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We thank Association Maladie Foie Enfants (AMFE) (Malakoff, France), Monaco Liver Disorder (MLD) (Monaco), Association "Pour Louis 1000 Foie Merci" (Fournet-Luisans, France), Association "Il était un foie" (Plouescat, France), Fondation Rumsey-Cartier (Genève, Switzerland) and FILFOIE for their support.

**Conflicts of Interest:** The authors declare no conflict of interest.
